Table 4.
A summary of included study characteristics
| Lead author | Year | Country | Follow-up (months) | Total (n) | Mean age (years) | Participants | Participants VA BCVA |
Interventions | Outcomes | Trial quality11 |
|---|---|---|---|---|---|---|---|---|---|---|
| Lashay62 | 2003 | Iran and UK | 3 | 67 | 33.6 | Macular edema in patients with Behçet’s | Group 1 = 0.430 Group 2 = 0.632 |
Acetazolamide 250 mg BD | BCVA Macular edema using FFA |
B |
| Whitcup60 | 1996 | USA | 4 | 40 | 41.0 | Intermediate and posterior uveitis patients with macular edema | Group 1 = (48) 20/100–2 Group 2 = (60) 20/63 |
Acetazolamide 500 mg BD | BCVA Macular edema using FFA |
B |
| Farber61 | 1994 | USA | 1 | 30 | 50.1 | Cystoid macular edema secondary to chronic iridocyclitis | Group 1 = 0.60 (0–22) Group 2 = 0.52 (0–47) |
Acetazolamide 500 mg BD | BCVA Posterior vitreous penetration ratios using vitreous fluorophotometry |
B |
Abbreviations: BCVA, best-corrected visual acuity; FFA, fundus fluorescein angiography; BD, twice daily.